Two drugs, developed by the same company, are repeatedly found to be equally effective at treating the developed world’s most common cause of blindness.
In Australia, one costs $50 per treatment, the other $2,000.
What do we get? The cheaper alternative?
Or a campaign to scare doctors and patients away from the cheap drug and extract billions across the world in the process?
The story of why Australian taxpayers are footing a $300 million-per-year bill for one drug — the biggest item on the PBS bill — while the vastly cheaper alternative is kept off-label.